Brann Darrell W, Greenbaum Lowell M, Mahesh Virendra B, Gao XiaoXing
Institute of Molecular Medicine and Genetics, Neurobiology Program, Department of Neurology, USA.
BMC Physiol. 2002 Apr 29;2:7. doi: 10.1186/1472-6793-2-7.
Previous work by our group and others has implicated a role for kinins in the ovulatory process. The purpose of the present study was to elucidate whether endogenous progesterone, which is an intraovarian regulator of ovulation, might be responsible for induction of the kinin system in the ovary during ovulation. The gonadotropin-primed immature rat was used as the experimental model, and the role of endogenous progesterone was explored using the antiprogestin, RU486.
The results of the study revealed that RU486 treatment, as expected, significantly attenuated ovulation. Activity of the kinin-generating enzyme, kallikrein, was elevated in the ovary in control animals prior to ovulation with peak values observed at 4 h post hCG, only to fall to low levels at 10 h, with a recovery at 20 h post hCG. RU486 treatment had no significant effect on ovarian kallikrein activity as compared to the control group. Total ovarian kininogen levels in control animals increased significantly at 12-14 h after hCG - coinciding with initiation of ovulation. Thereafter, ovarian kininogen levels fell to low levels at 20 h, only to show a rebound from 24-38 h post-hCG. RU486 treatment had no significant effect on the rise of total ovarian kininogen levels from 12-14 h after hCG; however, from 30-40 h post hCG, RU486-treated animals had significantly higher total ovarian kininogen levels versus control animals, suggesting that endogenous progesterone may act to restrain elevations of kininogens in the post-ovulatory ovary. This robust elevation of ovarian kininogen levels by RU486 was found to be primarily due to an increase in T-kininogen, which is a potent cysteine protease inhibitor.
Taken as a whole, these results suggest that endogenous progesterone does not regulate kallikrein activity or kininogens prior to ovulation, but may provide a restraining effect on T-kininogen levels in the post-ovulatory ovary.
我们团队及其他研究人员之前的工作表明激肽在排卵过程中发挥作用。本研究的目的是阐明作为排卵的卵巢内调节因子的内源性孕酮是否可能在排卵期间负责诱导卵巢中的激肽系统。促性腺激素预处理的未成熟大鼠被用作实验模型,并使用抗孕激素RU486来探究内源性孕酮的作用。
研究结果显示,正如预期的那样,RU486处理显著减弱了排卵。在排卵前,对照动物卵巢中激肽生成酶激肽释放酶的活性升高,在人绒毛膜促性腺激素(hCG)注射后4小时观察到峰值,仅在hCG注射后10小时降至低水平,并在hCG注射后20小时恢复。与对照组相比,RU486处理对卵巢激肽释放酶活性没有显著影响。对照动物的卵巢总激肽原水平在hCG注射后12 - 14小时显著增加,这与排卵开始时间一致。此后,卵巢激肽原水平在20小时降至低水平,仅在hCG注射后24 - 38小时出现反弹。RU486处理对hCG注射后12 - 14小时卵巢总激肽原水平的升高没有显著影响;然而,在hCG注射后30 - 40小时,接受RU486处理的动物的卵巢总激肽原水平显著高于对照动物,这表明内源性孕酮可能起到抑制排卵后卵巢中激肽原升高的作用。发现RU486使卵巢激肽原水平大幅升高主要是由于T - 激肽原增加,T - 激肽原是一种有效的半胱氨酸蛋白酶抑制剂。
总体而言,这些结果表明内源性孕酮在排卵前不调节激肽释放酶活性或激肽原,但可能对排卵后卵巢中的T - 激肽原水平起到抑制作用。